Cargando…
Do companies in the pharmaceutical supply chain earn excess returns?
Rising drug spending has led to increased calls to curtail drug costs. However, it is unclear where to target policy solutions. We estimated excess returns (the extent to which a firm’s profits are higher than expected given the risk associated with their investments) for manufacturers and middlemen...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780918/ https://www.ncbi.nlm.nih.gov/pubmed/33394339 http://dx.doi.org/10.1007/s10754-020-09291-1 |